iECURE
Mark Semanick currently serves as the VP Head of Technical Operations at iECURE, inc. since February 2022. Prior to this role, Mark held various senior positions including General Manager at Legend Biotech and Director of Manufacturing at WuXi Advanced Therapies, focusing on gene and cell therapies. Mark's earlier experience includes leadership roles at Shire, Merck, and WuXi AppTec, where responsibilities encompassed bioreactor operations, downstream operations, and drug development. Mark began professional career at Schering Plough and GSK, emphasizing cell culture. Mark holds a B.S. in Chemistry from Saint Francis University, earned in 2001.
This person is not in any offices
iECURE
1 followers
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.